NCT04022109 Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
| NCT ID | NCT04022109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Latvia |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2019-11-01 |
| Primary Completion | 2022-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2019-11-01 with a primary completion date of 2022-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.
Eligibility Criteria
Inclusion Criteria: * Patients with verified gastric cancer (Group 1 \& 2) * Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \& 5) * Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4) * Motivation to participate in the study * Physical status allowing volatile marker sampling and other procedures within the protocol * Signed consent Exclusion Criteria: * Known other active cancer * Ventilation problems, airway obstruction * Unwillingness or inability to co-operate
Contact & Investigator
Hossam Haick, PhD
PRINCIPAL INVESTIGATOR
TECHNION, Israel Institute for Technology
Frequently Asked Questions
Who can join the NCT04022109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04022109 currently recruiting?
Yes, NCT04022109 is actively recruiting participants. Contact the research team at marcis.leja@lu.lv for enrollment information.
Where is the NCT04022109 trial being conducted?
This trial is being conducted at São Paulo, Brazil, Santiago, Chile, Bogotá, Colombia, Riga, Latvia and 1 additional location.
Who is sponsoring the NCT04022109 clinical trial?
NCT04022109 is sponsored by University of Latvia. The principal investigator is Hossam Haick, PhD at TECHNION, Israel Institute for Technology. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.